Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
546. |
ECCT/23/04/02 | Shigella 53G study in Kenya Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study |
Principal Investigator(s) 1. Melissa Kapulu 2. Fredrick Sawe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
547. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
548. |
ECCT/19/04/01 | A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants. Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants |
Principal Investigator(s) 1. Mainga Hamaluba 2. Kosgei Josphat Site(s) in Kenya 1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county) 2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county) |
View |
549. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
View |
550. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
View |